NCT04171219: Talabostat and Pembrolizumab for the Treatment of Advanced Solid Cancers

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Therapeutic Antibody, Immunotherapy, Misc Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 12 Years and older (Child, Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patient has active symptomatic central nervous system (CNS) metastases that require treatment – see trial for details

Comments are closed.

Up ↑